ViralClear, AMRI Enter COVID-19 Partnership

ViralClear Pharmaceuticals, supported by Albany Molecular Research Inc., (AMRI), a global contract research, development, and manufacturing organization (CDMO), is undertaking research to investigate the potential of merimepodib to fight SARS-CoV-2, the virus that causes COVID-19, either as a stand-alone treatment or in combination with other antiviral agents or immune modulators.

“As part of our ongoing development and commercialization strategy we are delighted to be working with AMRI as our second U.S.-based active pharmaceutical ingredient (API) supplier. The rapid transfer, scale-up, and validation of merimepodib API manufacture is key to our future supply chain and commercialization strategy,” said Steve King, chief operating officer, ViralClear. “ViralClear is committed to using U.S.-based CDMOs for the development and commercialization of merimepodib.”

Christopher Conway, president, AMRI, said, “AMRI is proud to partner with ViralClear in this vital effort of seeking a potential treatment for COVID-19. Our team is committed to applying the expertise and experience we’re renowned for to help combat this complex global health challenge.”